Blood neurofilament light: a critical review of its application to neurologic disease

Neuronal injury is a universal event that occurs in disease processes that affect both the central and peripheral nervous systems. A blood biomarker linked to neuronal injury would provide a critical measure to understand and treat neurologic diseases. Neurofilament light chain (NfL), a cytoskeletal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Annals of clinical and translational neurology Ročník 7; číslo 12; s. 2508 - 2523
Hlavní autoři: Barro, Christian, Chitnis, Tanuja, Weiner, Howard L.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States John Wiley & Sons, Inc 01.12.2020
John Wiley and Sons Inc
Témata:
Antibodies
Biomarkers
Blood
Brain research
Disease
Gene expression
Nervous system
Neurological disorders
Physiology
Plasma
Review
Reviews
United States > US
ISSN:2328-9503, 2328-9503
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Neuronal injury is a universal event that occurs in disease processes that affect both the central and peripheral nervous systems. A blood biomarker linked to neuronal injury would provide a critical measure to understand and treat neurologic diseases. Neurofilament light chain (NfL), a cytoskeletal protein expressed only in neurons, has emerged as such a biomarker. With the ability to quantify neuronal damage in blood, NfL is being applied to a wide range of neurologic conditions to investigate and monitor disease including assessment of treatment efficacy. Blood NfL is not specific for one disease and its release can also be induced by physiological processes. Longitudinal studies in multiple sclerosis, traumatic brain injury, and stroke show accumulation of NfL over days followed by elevated levels over months. Therefore, it may be hard to determine with a single measurement when the peak of NfL is reached and when the levels are normalized. Nonetheless, measurement of blood NfL provides a new blood biomarker for neurologic diseases overcoming the invasiveness of CSF sampling that restricted NfL clinical application. In this review, we examine the use of blood NfL as a biologic test for neurologic disease.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Funding InformationCB is supported by a postdoctoral fellowship from the Swiss National Science Foundation (P400PM_191077). This study was funded in part by the U.S. Department of Defense (W81XWH‐18‐1‐0648 to TC), the National MS Society SUMMIT Consortium, and the Nancy Davis Center Without Walls.
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.51234